Abstract: Cationic porphycenes are conjugated, through a carboxylic-acid bearing moiety, with polylysine through an amide linkage. The novel porphycenes are effective in treating microbial populations in vitro or in vivo and topically as well as for sterilizing articles.

Abstract: Coupling two moles of a 2-halopyrrole in the presence of an inert aromatic solvent and a catalytically effective amount of a substantially pure copper catalyst provides high yields of the corresponding bipyrrole.

Abstract: Novel 9-substituted porphycene compounds are useful in photodynamic therapy.

Abstract: Porphycene compounds having the formula ##STR1## wherein each R is --(CH.sub.2).sub.n --X, n=1-10, X is OR.sup.1 and R.sup.1 is alkyl, aralkyl or aryl are useful as photosensitizer compounds in photodynamic therapy.

Abstract: A porphycene having the structure ##STR1## wherein each R.sup.1 is, independently, (a) --(CH.sub.2).sub.n --X, where n=1-4, X is OR.sup.2 and R.sup.2 is C.sub.1-6 alkyl, aralkyl or aryl; CN; OH; OSO.sub.2 R.sup.2 ; NH.sub.2 ; NHR.sup.2 ; NR.sub.2.sup.2 ; SH; SR.sup.2 ; S(O).sub.1-2 R.sup.2 ; COOH; CO.sub.2 R.sup.2 ; C(O)NH.sub.2 ; C(O)NHR.sup.2 ; C(O)NR.sub.2.sup.2 ; halogen; or CHO;(b) --(CH.sub.2).sub.m CH.dbd.CH.sub.2 where m is 0-2; or(c) --(CH.sub.2).sub.n --O--G where G is a mono- or oligosaccharide;(d) --(CH.sub.2).sub.2n --X, where X is an amino acid, oligopeptide covalently bonded by an ether-, ester- or amine-bond or --Y-- (CH.sub.2).sub.n -porphycene.sup.2 (porphycene.sup.2 being a compound of the same structure and Y is a direct bond; --O--; or --CH.dbd.CH.sub.2); or(e) where one, two or three of the substituents R.sup.1 are C.sub.1-6 alkyl or aryl and the remaining substituents are as above under (a)-(d), and salts and metal complexes thereof.

Abstract: A porphycene having the structure ##STR1## wherein each R.sup.1 is, independently, (a) --(CH.sub.2).sub.n --X, where n= 1-4, X is OR.sup.2 and R.sup.2 is C.sub.1-6 alkyl, aralkyl or aryl; CN; OH; OSO.sub.2 R.sup.2 ; NH.sub.2 ; NHR.sup.2 ; NR.sup.2.sub.2 ; SH; SR.sup.2 ; S(O).sub.1-2 R.sup.2 ; COOH; CO.sub.2 R.sup.2 ; C(O)NH.sub.2 ; C(O)NHR.sup.2 ; C(O)NR.sup.2.sub.2 ; halogen; or CHO;(b) --(CH.sub.2).sub.m CH.dbd.CH.sub.2 where m is 0-2; or(c) --(CH.sub.2).sub.n --O--G where G is a mono- or oligosaccharide;(d) --(CH.sub.2).sub.2n --X, where X is an amino acid, oligopeptide covalently bonded by an ether-, ester- or amine-bond or --Y--(CH.sub.2).sub.n -porphycene.sup.2 (porphycene.sup.2 being a compound of the same structure and Y is a direct bond; --O--; or --CH.dbd.CH.sub.2); or(e) where one, two or three of the substituents R.sup.1 are C.sub.1-6 alkyl or aryl and the remaining substituents are as above under (a)-(d), and salts and metal complexes thereof.

Abstract: New porphycene compounds useful as photodynamic therapy agents. The porphycene compounds have an active group capable of binding to proteins and peptides and facilitating decomposition of the porphycenes following therapy.

Abstract: A porphycene having the structure ##STR1## wherein each R.sup.1 is, independently, (a) --(CH.sub.2).sub.n --X, where n=1-4, X is OR.sup.2 and R.sup.2 is C.sub.1-6 alkyl, aralkyl or aryl; CN; OH; OSO.sub.2 R.sup.2 ; NH.sub.2 ; NHR.sup.2 ; NR.sub.2.sup.2 ; SH; SR.sup.2 ; S(O).sub.1-2 R.sup.2 ; COOH; CO.sub.2 R.sup.2 ; C(O)NH.sub.2 ; C(O)NHR.sup.2 ; C(O)NR.sub.2.sup.2 ; halogen; or CHO;(b) --(CH.sub.2).sub.m CH.dbd.CH.sub.2 where m is 0-2; or(c) --(CH.sub.2).sub.n --O--G where G is a mono- or oligosaccharide;(d) --(CH.sub.2).sub.2n --X, where X is an amino acid, oligopeptide covalently bonded by an ether-, ester- or amine-bond or --Y--(CH.sub.2).sub.n -porphycene.sup.2 (porphycene.sup.2 being a compound of the same structure and Y is a direct bond; --O--; or --CH.dbd.CH.sub.2); or(e) where one, two or three of the substituents R.sup.1 are C.sub.1-6 alkyl or aryl and the remaining substituents are as above under (a)-(d), and salts and metal complexes thereof.

Abstract: Dihydro- and tetrahydro-acetylene-cumulene porphycene compounds having the structure shown below ##STR1## are useful as photogynamic therapy agents.

Abstract: The therapeutic compositions of this invention comprise one or more porphycene compounds incorporated within liposomes. The method of this invention for treating cancer comprises administering a therapeutically effective amount of a porphycene derivative to a patient, and exposing an affected body area of the patient to a therapeutically sufficient amount of light having a wavelength of from 600 to 950 nm.

Abstract: The therapeutic compositions of this invention comprise one or more porphycene compounds incorporated within liposomes. The method of this invention for treating cancer comprises administering a therapeutically effective amount of a porphycene derivative to a patient, and exposing an affected body area of the patient to a therapeutically sufficient amount of light having a wavelength of from 600 to 950 nm.